SK452390A3 - Esters of thienyl carboxylic acids and amino alcohols, process for their preparation, intermediate products, pharmaceutical compositions containing same and their use - Google Patents

Esters of thienyl carboxylic acids and amino alcohols, process for their preparation, intermediate products, pharmaceutical compositions containing same and their use Download PDF

Info

Publication number
SK452390A3
SK452390A3 SK4523-90A SK452390A SK452390A3 SK 452390 A3 SK452390 A3 SK 452390A3 SK 452390 A SK452390 A SK 452390A SK 452390 A3 SK452390 A3 SK 452390A3
Authority
SK
Slovakia
Prior art keywords
thienyl
formula
tropanyl
compounds
compounds according
Prior art date
Application number
SK4523-90A
Other languages
Slovak (sk)
Other versions
SK279453B6 (en
Inventor
Rolf Banholzer
Rudolf Bauer
Richard Reichl
Original Assignee
Boehringer Ingelheim Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6389619&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK452390(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg
Publication of SK452390A3 publication Critical patent/SK452390A3/en
Publication of SK279453B6 publication Critical patent/SK279453B6/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Glass Compositions (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Disintegrating Or Milling (AREA)

Abstract

The new compounds of formula (I) (where A, R1, Ra and R2 are defined in the description) can be manufactured by processes known per se and used as the active ingredients of drugs.

Description

Estery tienylkarboxylových kyselín a aminoalkoholov, spôsob ich výroby, medziprodukty, farmaceutické prostriedky s ich obsahom a ich použitieEsters of thienylcarboxylic acids and aminoalcohols, process for their preparation, intermediates, pharmaceutical compositions containing them and their use

Oblasť technikyTechnical field

Vynález sa týka esterov tienylkarboxylových kyselín a aminoalkoholov, spôsobu ich výroby, farmaceutických prostriedkov s ich obsahom a ich použitia.The invention relates to thienylcarboxylic acid esters and aminoalcohols, to a process for their preparation, to pharmaceutical compositions containing them and to their use.

Doterajší stav technikyBACKGROUND OF THE INVENTION

Parasympatické nervy zabezpečujú dominantné bronchokonstrikčné neurálne riadenie hladkých svalov dýchacích ciest u ľudí. Cholinergický neurálny tonus je hlavnou reversibilnou zložkou chronických obštrukčných pulmonálnych chorôb (COPD) kde prostredníctvom podráždenia vágu tonusu cez deň tiež prispieva k nočným záchvatom astmy. Doba trvania účinku súčasných anticholinergických liečiv je niekedy nepostačujúca na poskytnutie uspokojivého udržania terapie u pacientov alebo na kontrolu nočnej astmy. Preto je tu klinická potreba vývoja novej anticholinergickej účinnej látky, ktorá má dlhšiu dobu trvania než doteraz známe liečivá.Parasympathetic nerves provide the dominant bronchoconstrictive neural control of airway smooth muscle in humans. Cholinergic neural tone is a major reversible component of chronic obstructive pulmonary disease (COPD) where it also contributes to nocturnal asthma attacks through daytime irritation of tonus vagus. The duration of action of current anticholinergic drugs is sometimes insufficient to provide satisfactory maintenance of therapy in patients or to control nocturnal asthma. Therefore, there is a clinical need for the development of a new anticholinergic active substance which has a longer duration than the known drugs.

Úlohou tohoto vynálezu je poskytnúť kvartérne amóniové zlúčeniny, ktoré sú anticholinergickými bronchodilatantmi s dlhotrvajúcim účinkom na liečenie pacientov s reverzibilnou obštrukčnou chorobou dýchacích ciest. Tieto zlúčeniny inhibujú exogénny acetylcholín (Ach)-indukovaný bronchospazmaticky trikrát účinnejšie než napríklad ipratropium bromid, ktorý je známy z doterajšieho stavu techniky a prejavujú sa značne dlhšou dobou trvania účinku než rovnaká dávka ipratropium bromidu. Doba trvania ochrany proti cholinergickej neurálnej bronchokonštrikcii je najvýznamnejším liečebným účinkom týchto látok.It is an object of the present invention to provide quaternary ammonium compounds which are long-acting anticholinergic bronchodilators for the treatment of patients with reversible obstructive airway disease. These compounds inhibit exogenous acetylcholine (Ach) -induced bronchospasm three times more efficiently than, for example, ipratropium bromide known in the art and exhibit a considerably longer duration of action than the same dose of ipratropium bromide. The duration of protection against cholinergic neural bronchoconstriction is the most significant therapeutic effect of these substances.

Podstata vynálezuSUMMARY OF THE INVENTION

Podstatu vynálezu tvoria estery tienylkarboxylových kyselín a aminoalkoholov všeobecného vzorca IThe present invention provides esters of thienylcarboxylic acids and aminoalcohols of formula (I)

-2(i)2 (i)

R1-C-CO-OA i R 1 -C-CO-OA i

kdewhere

A znamená skupinu všeobecného vzorca IIA is a group of formula II

kdewhere

Q znamená jednu z dvojväzbových skupín -CH2-CH2, -CH2-CH2-CH2-, -CH=CH-,Q represents one of the divalent groups -CH 2 -CH 2, -CH 2 -CH 2 -CH 2 -, -CH = CH-,

-CH - CHa-CH-CHa

R znamená alkyl s 1 až 4 atómami uhlíka, prípadne substituovaný atómom halogénu alebo hydroxyskupinou,R is C 1 -C 4 alkyl optionally substituted by halogen or hydroxy,

R' znamená alkyl s 1 až 4 atómami uhlíka a R a R' môžu spolu tvoriť alkylénový zvyšok s 4 až 6 atómami uhlíka, pričom sa pozitívny náboj dusíkového atómu vyrovnaná ekvivalentom aniónu X(’\R 'is C 1 -C 4 alkyl, and R and R' can be taken together to form a C 4 -C 6 alkylene moiety, whereby the positive charge of the nitrogen atom is offset by the anion equivalent of X ( ''

R1 znamená tienyl, fenyl, furyl, cyklopentyl alebo cyklohexyl, pričom všetky zvyšky môžu byť substituované metylovými zvyškami, tienyl a fenyl tiež atómami chlóru alebo flóruR 1 is thienyl, phenyl, furyl, cyclopentyl or cyclohexyl, each of these radicals to be substituted by methyl radicals, phenyl and thienyl also chlorine or fluorine

R2 znamená atóm vodíku, hydroxyskupinu, alkoxyskupina alebo alkylovú skupinu, obidve s 1 až 4 atómami vodíkuR2 represents a hydrogen atom, a hydroxy group, an alkoxy group or an alkyl group, both having 1 to 4 hydrogen atoms

-3Ra znamená atóm vodíku, atóm flóru, chlóru alebo metylovú skupinu.-3R a is a hydrogen atom, fluorine atom, chlorine atom or methyl.

Výhodné zlúčeniny podľa vynálezu sú tie, v ktorých R1 znamená 2-tienyl. Výhodné zlúčeniny podľa vynálezu sú tie, v ktorých R2 znamená hydroxyskupinu.Preferred compounds of the invention are those wherein R 1 is 2-thienyl. Preferred compounds are those wherein R 2 is hydroxy.

Medzi ďalšie výhodné zlúčeniny podľa vynálezu patria tie, kde A znamenáOther preferred compounds of the invention include those wherein A is

R a X() má význam, uvedený v nároku 1 a R'má význam uvedený v nároku 1, s výnimkou atómu vodíka.R and X () are as defined in claim 1 and R 'is as defined in claim 1, except for a hydrogen atom.

Zvlášť výhodné sú zlúčeniny, kde R1 znamená 2-tienyl a A znamená skupinu aleboParticularly preferred are compounds wherein R1 is 2-thienyl and A is or

-4vo forme 3α-, kde Xw znamená ekvivalent aniónu, s výhodou Br alebo CH3SO3' Podstatu vynálezu tvoria aj zlúčeniny všeobecného vzorcaIn the form of 3α-, wherein X w represents an anion equivalent, preferably Br or CH 3 SO 3.

vo forme 3α-, ako metobromidy alebo metometánsulfonáty.in the form of 3α-, such as metobromides or methanesulfonates.

Zlúčeniny podľa vynálezu sa pripravujú tak, že sa ester všeobecného vzorca IV aThe compounds of the invention are prepared by the ester of the formula IVa

R' r1_C_C0-0RR ' r 1_C_C0-0R

II

R2 (IV) kde R znamená alkyl s 1 až 4 atómami uhlíka a R1, R2 a r3 majú už uvedený význam, podrobí výmene esterových skupín s aminoalkoholom všeobecného vzorca VR 2 (IV) wherein R is C 1 -C 4 alkyl and R 1, R 2 and R 3 are as defined above, is subjected to the transesterification with the amino alcohol of formula V

CH.CH.

CH kdeCH kde

HO-CHHO-CH

CH.CH.

Q QQ Q

CHCH

-5Q má už uvedený význam, a Q znamená =NR alebo =NH, v inertnom organickom rozpúšťadle alebo v tavenine, za'prítomnosti katalyzátoru výmeny esterových skupín a získané zlúčeniny všeobecného vzorca VI saAnd Q is = NR or = NH, in an inert organic solvent or melt, in the presence of an ester exchange catalyst, and the compound of formula VI obtained is

a) v prípade, že Q znamená =NR, kvarternizujú pôsobením reaktívneho monoderivátu alkánu vzorca Z-(alkyI s 1 až 4 atómami uhlíka), kde Z je ľahko odštiepiteľná skupina, alebo sa(a) when Q is = NR, quaternize by treatment with a reactive mono derivative of an alkane of the formula Z- (C 1 -C 4 alkyl), wherein Z is an easily cleavable group, or

b) v prípade, že Q znamená =NH, kvarternizujú disubstituovaným alkánom vzorca Z-(alkylén s 4 až 6 atómami uhlíka)-Z bez izolácie medziproduktov.b) when Q is = NH, quaternize with a disubstituted alkane of formula Z- (C 4 -C 6 alkylene) -Z without isolation of the intermediates.

Podstatu vynálezu tvoria aj zlúčeniny všeobecného vzorca VI, kde Q, Q', Q, Ra, R1 a R^ majú význam uvedený vyššie, ako aj adičné soli týchto látok s kyselinami s výnimkou tropínesterov fenyl-2-tienylglykolovej, 2,2-dithienylglykolovej a 3,3'-ditienylglykolovej kyseliny.The present invention also relates to compounds of formula VI wherein Q, Q ', Q, R a , R 1 and R 6 are as defined above, as well as acid addition salts thereof with the exception of phenyl-2-thienylglycol, 2,2- dithienylglycolic acid and 3,3'-dithienylglycolic acid.

Ďalej podstatu vynálezu tvoria aj zlúčeniny všeobecného vzorca VI, ktorými sú: __ Furthermore, The present invention also compounds of formula VI, such as: _ _

-----S-----WITH

\\

-6Farmaceutický prostriedok s anticholinergickými účinkami, na liečbu ochorení dýchacích ciest a sínusovej bradykardie, ktorého podstatou je, že obsahuje zlúčeniny podľa vynálezu spolu s pomocnými látkami a/alebo nosičmi.A pharmaceutical composition with anticholinergic effects, for the treatment of respiratory diseases and sinus bradycardia, comprising a compound of the invention together with adjuvants and / or carriers.

Zlúčeniny podľa vynálezu sa používajú na prípravu farmaceutických prostriedkov s anticholinergickým účinkom, ďalej na liečbu ochorení dýchacích ciest a sínusovej bradykardie.The compounds of the invention are used for the preparation of pharmaceutical compositions with anticholinergic activity, further for the treatment of respiratory diseases and sinus bradycardia.

Na liečebné použitie sú vhodné najmä kvartérne deriváty, zatiaľ čo terciárne zlúčeniny sú vhodné aj ako medziprodukty.Quaternary derivatives are particularly suitable for therapeutic use, while tertiary compounds are also useful as intermediates.

Zlúčeniny podľa vynálezu sú cholinergné látky so silným a dlhodobým účinkom. Pri podaní dávok poriadku pg inhaláciou je možné dosiahnuť doby účinku až 24 hodín. Toxicita je približne rovnaká ako toxicita bežne dodávaného výrobku Ipratropiumbromidu, avšak liečebný účinok je silnejší.The compounds of the invention are cholinergic substances with a strong and long-lasting effect. When doses of the order of pg are administered by inhalation, an effect time of up to 24 hours can be achieved. The toxicity is approximately the same as that of the commercially available Ipratropium bromide product, but the therapeutic effect is stronger.

Zlúčeniny podľa vynálezu sa ako anticholinergné látky môžu použiť na liečenie chronickej obštruktívnej bronchitídy a ľahkej až stredne ťažkej astmy a ďalej na liečenie sínusovej bradykardie, spôsobenej podráždením vagu.The compounds of the invention may be used as anticholinergic agents for the treatment of chronic obstructive bronchitis and mild to moderate asthma, and for the treatment of sinus bradycardia caused by vagal irritation.

Pri ochoreniach dýchacích ciest prichádza do úvahy predovšetkým inhalačné použitie zlúčenín podľa vynálezu, najmä kvarťérnych zlúčenín, čím je možné vylúčiť do značnej miery akékoľvek vedľajšie účinky. Pri bradykardii sa látky podávajú s výhodou vnútrožilovo alebo perorálne. V tomto prípade je výhodné, že zlúčeniny podľa vynálezu nie sú ovplyvňované pohybmi žalúdka a čriev.In respiratory diseases, the inhalation use of the compounds according to the invention, in particular the quaternary compounds, is in particular possible, so that any side effects can be largely avoided. In bradycardia, the agents are preferably administered intravenously or orally. In this case, it is preferred that the compounds of the invention are not affected by gastric and bowel movements.

Pri spracovaní liekovej formy sa k účinným látkam pridávajú známe pomocné látky a/alebo nosiče. Na inhalačné podanie ide napríklad o suspenzie v skvapalnených hnacích plynoch, prostriedky s obsahom lipozómov alebo prolipozómov, injekčné roztoky, tablety, dražé, kapsuly alebo prášky na použitie vo zvyčajných inhalačných prístrojoch.When processing the dosage form, known excipients and / or carriers are added to the active ingredients. For administration by inhalation, for example, suspensions in liquefied propellants, liposome or proliposome formulations, injectable solutions, tablets, dragees, capsules or powders for use in conventional inhaler devices are provided.

Ďalej budú uvedené príklady zloženia liekových foriem. Údaje sú uvedené v % hmotnostných.Examples of the formulation of the dosage forms will be given below. Data are in% by weight.

-7 1. Aerosol v dávkovacom balení účinná látka podľa vynálezu 0,005 sorbitan trioleát 0,1 monofluórtrichlórmetán a difluórdichlórmetán v pomere 2:3 do 1001. Aerosol in a dosage package active ingredient according to the invention 0.005 sorbitan trioleate 0.1 monofluorotrichloromethane and difluorodichloromethane in a ratio of 2: 3 to 100

Suspenzia sa plní do nádobky, opatrenej dávkovacím ventilom. Pri jednom uvedení ventilu do činnosti sa s výhodou uvoľní 50 μΙ suspenzie, roztok môže obsahovať aj vyššiu dávku účinnej látky, napríklad 0,02 % hmotnostných.The suspension is filled into a container fitted with a metering valve. One actuation of the valve preferably releases 50 μΙ of the suspension, the solution may also contain a higher dose of the active ingredient, for example 0.02% by weight.

2. Tablety účinná látka podľa vynálezu 0,05 koloidná kyselina kremičitá 0,95 mliečny cukor 65,00 zemiakový škrob 28,00 polyvinylpyrolidón 3,00 sodná soľ glykolátu celulózy 2,00 stearan horečnatý 1,002. Tablets Active ingredient according to the invention 0.05 Colloidal silicic acid 0.95 Milk sugar 65.00 Potato starch 28.00 Polyvinylpyrrolidone 3.00 Sodium cellulose glycolate 2.00 Magnesium stearate 1.00

Zmes sa spracuje bežným spôsobom na tablety s hmotnosťou 200 mg. Výhodné vlastnosti zlúčenín podľa vynálezu je možné dokázať napríklad pri brzdení broncholýzy u králika, u ktorého bol vyvolaný kŕč vnútrožilovým podaním acetylcholínu. Po vnútrožilovom podaní zlúčenín podľa vynálezu v dávke 3 pg/kg vnútrožilovo bol maximálny účinok po 10 až 40 minútach. Ani po 5 hodinách ešte účinok nepoklesol na polovicu, to znamená, že pokles účinku na polovicu trvá podstatne dlhšiu dobu ako 5 hodín, ako je možné dokázať percentami účinku jednotlivých dávok po 5 hodinách.The mixture is processed to 200 mg tablets in a conventional manner. Advantageous properties of the compounds of the invention can be demonstrated, for example, in inhibiting broncholysis in a rabbit in which convulsions have been induced by intravenous administration of acetylcholine. Following intravenous administration of the compounds of the invention at 3 µg / kg intravenously, the maximal effect was 10 to 40 minutes. Even after 5 hours, the effect has not yet decreased by half, i.e. the decrease in effect in half lasts considerably longer than 5 hours, as can be shown by the percent action of the individual doses after 5 hours.

..8zlúčenina zvyšok účinku v %..8 compound residual effect in%

AA

BB

CC

DD

EE

FF

GG

-9Zlúčenina vzorca-9Compound of formula

HO-C-CO-AHO-C-CO-A

RR

Zlúčenina ACompound A

R1 R 1

3-tienyl3-thienyl

2-tienyl2-thienyl

3-tienyl3-thienyl

2-tienyl2-thienyl

Br®Br®

-o-about

CH3-^-CH(CH3)2 cyklopentytCH 3 -? - CH (CH 3 ) 2 cyclopentyl

Br®Br®

-o-about

CH3-^-CH2-CH2F cyklopentylCH 3 -? - CH 2 -CH 2 F cyclopentyl

-10Zlúčenina C-10Compound C

Poznámky:notes:

1) U zlúčenín, v ktorých R1 má odlišný význam od 2-tienylového zvyšku, ide o racemáty.1) Compounds in which R 1 is different from the 2-thienyl radical are racemates.

2) Ide vždy o 3a-zlúčeniny.2) These are always 3a-compounds.

Na výrobu zlúčenín podľa vynálezu je možné použiť zásadne známe postupy.In principle, known methods can be used to produce the compounds of the invention.

Výmena esterovej skupiny sa uskutočňuje pri vyššej teplote v organickom rozpúšťadle, napríklad toluéne, xyléne, heptáne alebo v tavenine, pričom ako katalyzátor je možné použiť silnú bázu, napríklad metoxid sodíka, etoxid sodíka, hydrid sodíka alebo kovový sodík. Na odstránenie uvoľneného nižšieho alkoholu zo zmesi sa použije znížený tlak alebo azeotropné oddestilovanie alkoholu. Reakcia sa zvyčajne uskutočňuje pri teplote, neprekračujúcej 95 °C. Často prebieha reakcia výhodnejšie v tavenine.The ester group is exchanged at a higher temperature in an organic solvent such as toluene, xylene, heptane or melt, and a strong base such as sodium methoxide, sodium ethoxide, sodium hydride or sodium metal may be used as the catalyst. A reduced pressure or azeotropic distillation of the alcohol is used to remove the released lower alcohol from the mixture. The reaction is usually carried out at a temperature not exceeding 95 ° C. Often, the reaction is preferably carried out in the melt.

Z adičných solí terciárnych amínov s kyselinami je možné v prípade potreby získať známym spôsobom voľné bázy pôsobením vhodných zásad. Kvarternizácia sa uskutočňuje vo vhodnom rozpúšťadle, napríklad acetonitrile alebo v zmesi acetonitrilu a metylénchloridu, s výhodou pri teplote miestnosti. Ako kvarternizačné činidlo sa s výhodou použije zodpovedajúci alkylhalogenid, ako alkylbromid. Produkty, v ktorých Q' má význam NH, slúžia ako východiskové látky pre tie zlúčeniny, v ktorých R a R’ spoločne tvoria alkylénový zvyšok so 4 až 6 atómami uhlíka. Premenu na terciárnu a potom kvartérnu zlúčeninu je po- 11 tom možné uskutočniť pôsobením 1,4-, 1,5- alebo 1,6-dihalogénalkánu bez izolácie medziproduktu.If desired, free bases can be obtained from the tertiary amine addition salts with acids by treatment with suitable bases in a known manner. The quaternization is carried out in a suitable solvent, for example acetonitrile or in a mixture of acetonitrile and methylene chloride, preferably at room temperature. The quaternizing agent is preferably a corresponding alkyl halide such as an alkyl bromide. The products in which Q 'has the meaning of NH serve as starting materials for those compounds in which R and R' together form an alkylene radical having 4 to 6 carbon atoms. Conversion to a tertiary and then quaternary compound can then be accomplished by treatment with 1,4-, 1,5- or 1,6-dihaloalkane without isolation of the intermediate.

Východiskové látky môžu, pokiaľ ešte neboli opísané, byť získané analogickými spôsobmi ako známe zlúčeniny.The starting materials may, if not already described, be obtained by analogous methods to known compounds.

Napríklad je možné získať:For example, you can get:

metylester kyseliny di-(2-tienyl)glykolovej z dimetylesteru kyseliny šťavelovej a 2-tienylmagnéziumbromidu, etylester kyseliny di-(2-tienyI)glykolovej z kyseliny (2-tienyl)glyoxylovej a 2tienyllítia, etylester kyseliny hydroxyfenyl-(2-tienyl)octovej z metylesteru kyseliny fenylglyoxylovej a 2-tienylmagnéziumbromidu alebo z metylesteru kyseliny (2-tienyl)g1yoxyIovej a fenylmagnéziumbromidu.methyl di- (2-thienyl) glycolic acid from dimethyl oxalic acid and 2-thienylmagnesium bromide; from methylglycylic acid methyl ester and 2-thienylmagnesium bromide; or (2-thienyl) glyoxylate and phenylmagnesium bromide methyl ester.

Podobným spôsobom je možné uviesť do reakcie aj metylester kyselinyIn a similar manner, the methyl ester can also be reacted

2- tienylglyoxylovej a cyklohexyl- alebo cyklopentylmagnéziumbromid.2-thienylglyoxyl and cyclohexyl- or cyclopentylmagnesium bromide.

Takéto aminoalkoholy je možné vyrobiť rôznym spôsobom.Such aminoalcohols can be prepared in various ways.

Výroba pseudoskopínu bola opísaná v publikácii M. Polonovski a ďalší, Bull, Soc. Chim. 43, 79 (1928).The production of pseudoscopy has been described by M. Polonovski et al., Bull, Soc. Chim. 43, 79 (1928).

Pseudotropenol je možné získať trakčnou kryštalizáciou zo zmesi, ktorá bola opísaná v publikáciách V. Hayakawa a ďalší, J. Amer. Chem. Soc. 1978, 100(6), 1786 a R. Noyori a ďalší, J. Amer. Chem. Soc. 1974, 96(10), 3336, je tiež možné tieto zmesi destilovať.Pseudotropenol can be obtained by traction crystallization from the mixture described by V. Hayakawa et al., J. Amer. Chem. Soc. 1978, 100 (6), 1786 and R. Noyori et al., J. Amer. Chem. Soc. 1974, 96 (10), 3336, it is also possible to distill these mixtures.

Pri použití 2- alebo 3-furylglyoxylnitrilu je možné okrem kyseliny 2- aleboWhen 2- or 3-furylglyoxylnitrile is used, it is possible, in addition to 2- or 3-acid

3- furylglyoxylovej získať aj zvyčajným spôsobom zodpovedajúce metylestery. Z týchto látok je potom možné získať opísaným spôsobom pri použití organických derivátov kovov 2- alebo 3-brómtiofénu aj zodpovedajúce estery kyseliny glykolovej. Organické zlúčeniny kovov, získané z 2-, 3- alebo 4-halogénpyridínu je možné uviesť do reakcie s metylesterom kyseliny 2- alebo 3-tienylglyoxylovej za vzniku zodpovedajúcich esterov kyseliny glykolovej.3-furylglyoxyl can also be obtained in the usual manner by the corresponding methyl esters. The corresponding glycolic esters can then also be obtained from these materials using the organic metal derivatives of 2- or 3-bromothiophene as described above. The organic metal compounds obtained from 2-, 3- or 4-halopyridine can be reacted with 2- or 3-thienylglyoxylic acid methyl ester to give the corresponding glycolic acid esters.

Estery kyseliny tienylglykolovej, v ktorých obsahuje tiofénový kruh atóm fluóru v polohe 2 alebo 3, je možné vyrobiť napríklad z 2- alebo 3-fluórtiofénuThienylglycolic acid esters in which the thiophene ring contains a fluorine atom in the 2 or 3 position can be prepared, for example, from 2- or 3-fluorothiophene

-12bromáciou na 2-bróm-3-fluór- alebo 2-bróm-5-fluórtiofén s následným prevedením na organickú zlúčeninu kovu a reakciou s príslušným esterom kyseliny glyoxylovej za získania požadovaného esteru kyseliny glykolovej.By bromination to 2-bromo-3-fluoro- or 2-bromo-5-fluorothiophene followed by conversion to an organic metal compound and reaction with an appropriate glyoxylic ester to give the desired glycolic ester.

2-fluórtiofén a 3-fluórtiofén je možné premeniť na estery kyseliny glyoxylovej spôsobom podľa publikácie Unterhalt, Árch. Pharm. 322, 839 (1989) a získané estery je možné, ako už bolo opísané uviesť do reakcie s 2- alebo 3tienylovými derivátmi na estery kyseliny glykolovej. Vhodnou voľbou zložiek je možné získať symetricky substituované estery kyseliny ditienylglykolovej.2-Fluorothiophene and 3-Fluorothiophene can be converted to glyoxylic esters according to Unterhalt, Ar. Pharm. 322, 839 (1989) and the esters obtained can be reacted as described above with 2- or 3-thienyl derivatives to give glycolic acid esters. Symmetrically substituted dithienylglycolic esters can be obtained by suitable choice of components.

Ďalší postup vedie analogicky ku kondenzácii benzoínu a analogickej reakcii s kyselinou benzylovou.A further procedure leads analogously to the condensation of benzoin and an analogous reaction with benzylic acid.

Praktické uskutočnenie vynálezu bude vysvetlené nasledujúcimi príkladmi.The following examples illustrate the invention.

Príklady uskutočnenia vynálezuDETAILED DESCRIPTION OF THE INVENTION

Skopínester kyseliny di-(2-tienyl)glykôlovejDi- (2-thienyl) glycolic acid scopine ester

50,87 g, 0,2 mol metylesteru kyseliny di-(2-tienyl)glykolovej a 31,04 g, 0,2 mol skopínu sa rozpustí v 100 ml absolútneho toluénu a potom sa po niekoľkých podieloch pridá 1,65 g, 0,071 gramatómu sodíka pri teplote kúpeľa 90 °C. Pri teplote 78 až 90 °C a tlaku 0,5.105 Pa (500 mbar) sa z reakčnej zmesi oddestiluje vznikajúci metanol. Po reakčnej dobe 5 hodín sa reakčná zmes vmieša do zmesi ľadu a kyseliny chlorovodíkovej. Kyslá fáza sa oddelí, alkalizuje uhličitanom sodným a voľná báza sa extrahuje metylénchloridom. Po vysušení síranom sodným sa metylénchlorid oddestiluje za zníženého a odparok sa nechá prekryštalizovať z acetonitrilu. Vo výťažku 44,7 % teoretického množstva sa týmto spôsobom získa 33,79 g béžového kryštalického produktu s teplotou topenia 149 až 150 °C (acetonitril).50.87 g, 0.2 mol of methyl di- (2-thienyl) glycolic acid ester and 31.04 g, 0.2 mol of scopine are dissolved in 100 ml of absolute toluene and then 1.65 g, 0.071 are added in several portions. of sodium gramamatome at a bath temperature of 90 ° C. At a temperature of 78-90 DEG C. and a pressure of 0.5.10 5 Pa (500 mbar), the reaction mixture was distilled off formed methanol. After a reaction time of 5 hours, the reaction mixture is stirred into a mixture of ice and hydrochloric acid. The acid phase was separated, basified with sodium carbonate and the free base was extracted with methylene chloride. After drying over sodium sulfate, the methylene chloride is distilled off under reduced pressure and the residue is recrystallized from acetonitrile. Yield: 33.79 g of a beige crystalline product (44.7% of theory); m.p. 149 DEG-150 DEG C. (acetonitrile).

Príklad 2Example 2

Skopínester kyseliny di-(2-tienyl)glykolovejDi- (2-thienyl) glycolic acid scopine ester

- 1312,72 g, 0,05 mol metylesteru kyseliny di-(2-tienyl)glykolovej a 7,76 g, 0,05 mol skopínu sa zahrieva v kúpeli s teplotou 70 °C za použitia vodnej vývevy až do roztavenia. Do taveniny sa pridá 2,70 g, 0,05 mol metoxidu sodíka a zmes sa zahrieva za použitia vodnej vývevy 1 hodinu na kúpeli s teplotou 70 °C a potom ešte ďalšiu hodinu na kúpeli s teplotou 90 °C. Stuhnutá tavenina sa pri riadenej teplote zmieša so zmesou 100 ml vody a 100 ml metylénchloridu a metylénchloridová fáza sa opakovane extrahuje vodou a potom zodpovedajúcim množstvom zriedenej kyseliny chlorovodíkovej. Vodné fázy sa zlejú, po pridaní zodpovedajúceho množstva uhličitanu sodného sa metylénchloridom extrahuje skopínester kyselinu di-(2-tienyl)glykolovej a metylénchloridový roztok sa vysuší síranom sodným a bežným spôsobom sa pripraví hydrochlorid. Kryštáliky sa odfiltrujú za odsávania, premyjú sa acetónom a sušia za zníženého tlaku pri 35 °C. Vo výťažku 53,1 % sa získa po prekryštalizovaní z metanolu 10,99 g svetlobéžových kryštálov s teplotou topenia 238 až 241 °C za rozkladu. Z hydrochloridu je možné bežným spôsobom získať voľnú látku.1312.72 g, 0.05 mol of di- (2-thienyl) glycolic acid methyl ester and 7.76 g, 0.05 mol of scopine are heated in a 70 ° C bath using a water pump until melting. Sodium methoxide (2.70 g, 0.05 mol) was added to the melt and the mixture was heated using a water pump for 1 hour in a 70 ° C bath and then for an additional hour in a 90 ° C bath. The solidified melt is mixed with a mixture of 100 ml of water and 100 ml of methylene chloride at a controlled temperature, and the methylene chloride phase is repeatedly extracted with water and then with an appropriate amount of dilute hydrochloric acid. The aqueous phases are decanted, after addition of the appropriate amount of sodium carbonate, the di- (2-thienyl) glycolic acid scopine ester is extracted with methylene chloride and the methylene chloride solution is dried over sodium sulphate and the hydrochloride is prepared in a conventional manner. The crystals were filtered off with suction, washed with acetone and dried under reduced pressure at 35 ° C. In a yield of 53.1%, after recrystallization from methanol, 10.99 g of pale beige crystals with a melting point of 238 DEG-241 DEG C. are obtained with decomposition. The free material can be obtained from the hydrochloride in a conventional manner.

Príklad 3Example 3

Skopínester kyseliny di-(2-tienyl)glykolovejDi- (2-thienyl) glycolic acid scopine ester

38,15 g, 0,15 mol metylesteru kyseliny di-(2-tienyl)-glyko!ovej a 23,28 g, 0,15 mol skopínu sa zmieša, pridá sa 0,34 g, 0,015 gramatómu sodíka a zmes sa roztaví za použitia vodnej vývevy na kúpeli s teplotou 90 °C. Reakcia trvá 2,5 hodiny. Potom sa pridá 100 ml absolútneho etanolu a zmes sa mieša pri teplote kúpeľa 90 °C tak dlho, až vznikne roztok, tento roztok sa potom ochladí na teplotu miestnosti a pridá sa zmes ľadu a kyseliny chlorovodíkovej, ochladenej ľadom. Vykryštalizovaný hydrochlorid bázického esteru sa odfiltruje za odsávania a premyje sa malým množstvom vody a dostatočným množstvom dietyléteru. Fáza filtrátu sa oddelí a vodná fáza sa extrahuje dietyléterom. Odfiltrovaný hydrochlorid sa uvedie do suspenzie v kyslej vodnej fáze a za riadenia teploty sa pridaním uhličitanu sodného premení na voľnú látku, ktorá sa extrahuje metylénchloridom. Metylénchloridové fázy sa vysušia síranom sodným a oddestilujú, získaný kryštalický materiál sa čistí aktívnym uhlím a nechá prekryštalizovať z38.15 g (0.15 mol) of di- (2-thienyl) -glycolic acid methyl ester and 23.28 g (0.15 mol) of scopine are mixed, 0.34 g (0.015 gram) of sodium are added and the mixture melted. using a water pump on a 90 ° C bath. The reaction takes 2.5 hours. 100 ml of absolute ethanol are then added and the mixture is stirred at a bath temperature of 90 ° C until a solution is formed, which solution is then cooled to room temperature and a mixture of ice-cooled ice-hydrochloric acid is added. The crystallized basic ester hydrochloride is filtered off with suction and washed with a little water and a sufficient amount of diethyl ether. The filtrate phase is separated and the aqueous phase is extracted with diethyl ether. The filtered hydrochloride is suspended in the acidic aqueous phase and converted to the free material by addition of sodium carbonate under temperature control, which is extracted with methylene chloride. The methylene chloride phases are dried over sodium sulphate and distilled off, the crystalline material obtained is purified with activated carbon and recrystallized

-14acetonitrilu. Vo výťažku 70,1 % sa získa 39,71 g svetložltých kryštálov s teplotou topenia 148 až 149 °C.-14acetonitrilu. 39.71 g of pale yellow crystals with a melting point of 148-149 ° C are obtained in a yield of 70.1%.

Tabuľka ITable I

Zlúčeniny všeobecného vzorcaCompounds of general formula

HO-C-CO-OAHO-C-CO-OA

II

R1 R 1

č. no. A A R1 R1 báza base teplota topenia °C hydrochlorid mp ° C hydrochloride 1 1 3a-(6p,7p-epoxy)tropanyl 3a- (6?, 7? Epoxy) tropanyl 2-tienyl 2-thienyl 149-150 149-150 238-241 238-241 2 2 3a-tropanyl 3-tropanyl 2-tienyl 2-thienyl 167-168 167-168 253 253 3 3 3a-(6,7-dehydro)tropanyl 3a- (6,7-dehydro) tropanyl 2-tienyl 2-thienyl 164-165 164-165 4 4 3a-(N-p-fluóretyl)nortropanyl 3a- (N-p-fluoro-ethyl) nortropanyl 2-tienyl 2-thienyl 236 236 5 5 3a-(N-izopropyl)granatanyl 3a- (N-isopropyl) granatanyl 2-tienyl 2-thienyl 232 232 6 6 3a -(N-izopropyl)nortropanyl 3a - (N-Isopropyl) nortropanyl 2-tienyl 2-thienyl 250 250 7 7 3a-(6p,7p-epoxy)-N-izopropylnor- 3a- (6?, 7? Epoxy) -N-izopropylnor- tropanyl tropanyl 2-tienyl 2-thienyl 206 206 8 8 3a-(6p,7p-epoxy)-N-etyl- 3a- (6?, 7? Epoxy) -N-ethyl- nortropanyl nortropanyl 2-tienyl 2-thienyl 212-213 212-213 9 9 3a-(A-etyl)nortropanyl 3a- (S-ethyl) nortropanyl 2-tienyl 2-thienyl 256-7 256-7 10 10 3a-(N,N-metyl)granatanyl 3a- (N, N-methyl) granatanyl 2-tienyl 2-thienyl 241 241 11 11 3a-(6p,7p-epoxy)-N-p-fluór- 3a- (6?, 7? Epoxy) -N-p-fluoro- etylnortropanyl etylnortropanyl 2-tienyl 2-thienyl 188-190 188-190 12 12 3a-(6p,7p*epoxy)-N-n- 3a- (6?, 7? * Epoxy) -N-n- propylnortropanyl propylnortropanyl 2-tienyl 2-thienyl 104-106 104-106

-15R1 báza teplota topenia °C hydrochlorid-15R 1 base melting point ° C hydrochloride

3a-(6p,7p-epoxy)-N-n-butyl-3a- (6?, 7? Epoxy) -N-n-butyl

nortropanyl nortropanyl 2-tienyl 2-thienyl 225-227 225-227 3a-(6a,7p-epoxy)tropanyl 3a (6a, 7p-epoxy) tropanyl fenyl phenyl 246-247 246-247 3a-tropanyi 3-tropanyi fenyl phenyl 243-244 243-244 3a-(N-p~fluóretyl)nortropanyl 3a- (N-p-fluoro-ethyl) nortropanyl fenyl phenyl 219-220 219-220 3a-(6,7-dehydro)tropanyl 3a- (6,7-dehydro) tropanyl fenyl 181-183 phenyl 181-183 3a-(N-etyl)nortropanyl 3a- (N-ethyl) nortropanyl fenyl phenyl 231-232 231-232 3a-(N-izopropyl)nortropanyl 3a- (N-isopropyl) nortropanyl fenyl phenyl 246-247 246-247 3a-tropanyl 3-tropanyl cyklohexyl cyclohexyl 260 260 3a-(N-p-fluóretyl)nortropanyl 3a- (N-p-fluoro-ethyl) nortropanyl cyklohexyl cyclohexyl 203-204 203-204 3a-(6p,7p-epoxy)tropanyl 3a- (6?, 7? Epoxy) tropanyl cyklopentyl cyclopentyl 237 237 3a-tropanyl 3-tropanyl cyklopentyl cyclopentyl 260 260 3oc-(N-p-fluóretyl)nortropanyl 3oc- (N-p-fluoro-ethyl) nortropanyl cyklopentyl cyclopentyl 182-183 182-183 3a-(N-etyl)nortropanyl 3a- (N-ethyl) nortropanyl cyklopentyl cyclopentyl 227-228 227-228 3a-(N-izopropyl)nortropanyl 3a- (N-isopropyl) nortropanyl cyklopentyl cyclopentyl 174-175 174-175 3a-(6p,7p-epoxy)tropanyl 3a- (6?, 7? Epoxy) tropanyl 2-tienyl 2-thienyl 240-242 240-242 3a-tropanyl 3-tropanyl 2-tienyl 2-thienyl 217-219 217-219 3a-(6,7-dehydro)tropanyl 3a- (6,7-dehydro) tropanyl 2-tienyl 2-thienyl 233-235 233-235 3a-(6,7-dehydro)tropanyl 3a- (6,7-dehydro) tropanyl 3-tienyl 3-thienyl 247-248 247-248 3a-(6p,7p-epoxy)tropanyl 3a- (6?, 7? Epoxy) tropanyl 3-tienyí 3-thienyl 242-243 242-243 3a-(6p,7p-epoxy)tropanyl 3a- (6?, 7? Epoxy) tropanyl 2-furyl 2-furyl 3a-(6,7-dehydro)tropanyl 3a- (6,7-dehydro) tropanyl 2-furyl 2-furyl 3a-tropanyl 3-tropanyl 2-furyl 2-furyl 3a-tropanyl 3-tropanyl 2-pyridyl 2-pyridyl 3a-(6p7p-epoxy)tropanyl 3a (6p7p-epoxy) tropanyl 2-pyridyl 2-pyridyl 3a-(6,7-dehydro)tropanyí 3a- (6,7-dehydro) tropanyí 2-pyridyl 2-pyridyl 3a-tropanyl 3-tropanyl 3-tienyl 3-thienyl

Č. No. A A báza base teplota topenia °C hydrochlorid mp ° C hydrochloride 39 39 3a-(6,7-dehydro)tropanyl 3a- (6,7-dehydro) tropanyl cyklopentyl cyclopentyl 40 40 3a-(6p,7p-epoxy)tropanyl 3a- (6?, 7? Epoxy) tropanyl cyklohexyl cyclohexyl 41 41 3a-(6,7-dehydro)tropanyl 3a- (6,7-dehydro) tropanyl cyklohexyl cyclohexyl

Poznámka: všetky hydrochľoridy sa topia za rozkladu.Note: all hydrochloride melts with decomposition.

Príklad 4Example 4

Metobromid skopínesteru kyseliny di-(2-tienyl)glyko!ovejDi- (2-thienyl) glycolic acid scopine ester metobromide

10,0 g, 0,0265 mol skopínesteru kyseliny di-(2-tienyl)-glykolovej sa rozpustí v zmesi 20 ml bezvodého metylénchloridu a 30 ml bezvodého acetonitrilu, pridá sa 12,8 g 0,1325 mol metylbromidu vo forme 50%-ného roztoku v bezvodom acetonitrile a reakčná zmes sa pevne uzavrie do reakčnej nádoby a nechá sa stáť 24 hodín pri teplote miestnosti. V priebehu tejto doby sa vytvorí kryštalická zrazenina. Táto zrazenina sa odfiltruje za odsávania, premyje sa metylénchloridom a potom sa suší za zníženého tlaku pri teplote 35 °C. Po vysušení pri teplote 111 °C a prekryštalizovaní zo zmesi metanolu a acetónu sa získa biely kryštalický produkt s teplotou topenia 217 až 218 °C.Di- (2-thienyl) glycolic acid scopine ester (10.0 g, 0.0265 mol) is dissolved in a mixture of 20 ml of anhydrous methylene chloride and 30 ml of anhydrous acetonitrile, and 12.8 g of 0.1325 mol of methyl bromide is added as 50% - The reaction mixture was sealed into anhydrous acetonitrile and the reaction mixture was sealed firmly in the reaction vessel and allowed to stand at room temperature for 24 hours. During this time, a crystalline precipitate forms. The precipitate was filtered off with suction, washed with methylene chloride and then dried under reduced pressure at 35 ° C. After drying at 111 ° C and recrystallization from methanol-acetone, a white crystalline product is obtained with a melting point of 217-218 ° C.

Tabuľka IITable II

Kvartérne zlúčeniny vzorcaQuaternary compounds of formula

HO-C-CO-OAHO-C-CO-OA

I.I.

R1 R 1

-17č.-17C.

R1 tepl. top. °CR 1 temp. top. ° C

1 1 3a-(6p7p-epoxy)tropanylmetobromid 3a (6p7p-epoxy) tropanylmetobromid 2-tienyl 2-thienyl 217-218 217-218 2 2 3a-tropanyl-metobromid 3-tropanyl-methobromide 2-tienyl 2-thienyl 263-264 263-264 3 3 3a-(67-dehydro)tropanyl-metobromid 3a- (67-dehydro) tropanyl-methobromide 2-tienyl 2-thienyl 191-192 191-192 4 4 3a-(N-p-fluóretyl)nortropanylmetobromid 3a- (N-p-fluoro-ethyl) nortropanylmetobromid 2-tienyl 2-thienyl 242-243 242-243 5 5 3a-tropanyl-P-fluórmetobromid 3-tropanyl-P-fluórmetobromid 2-tienyl 2-thienyl 214-215 214-215 6 6 3a-(N-izopropyl)granatanyl-metobromid 3a- (N-isopropyl) granatanyl-methobromide 2-tienyl 2-thienyl 242-243 242-243 7 7 3a-(N-izopropyl)nortropanyl-metobromid 3a- (N-isopropyl) nortropanyl-methobromide 2-tienyl 2-thienyl 229-230 229-230 8 8 3a-(6p,7p-epoxy)-N-izopropylnortropanyl- metobromid 3a- (6?, 7? Epoxy) -N-izopropylnortropanyl- methobromide 2-tienyl 2-thienyl 223-224 223-224 9 9 3a-(6p,7p-epoxy)-etyl-nortropanylmetobromid 3a- (6?, 7? Epoxy) -ethyl nortropanylmetobromid 2-tienyl 2-thienyl 215-216 215-216 10 10 3a-(N-etyl)nortropanyl-metobromid 3a- (N-ethyl) nortropanyl-methobromide 2-tienyl 2-thienyl 260-261 260-261 11 11 3a-(N-metyl)granatanyl-metobromid 3a- (N-methyl) granatanyl-methobromide 2-tienyl 2-thienyl 246-247 246-247 12 12 3a-(6p,7p-epoxy)-N-p-fluór-etylnortropanyl- metobromid 3a- (6?, 7? Epoxy) -N-p-fluoro-etylnortropanyl- methobromide 2-tienyl 2-thienyl 182-183 182-183 13 13 3a-(6p,7p-epoxy)-N-n-propyl-nortropanyl- metobromid 3a- (6?, 7? Epoxy) -N-n-propyl-nortropanyl- methobromide 2-tienyl 2-thienyl 209-210 209-210 14 14 3a-tropanyl-p-hydroxyetylbromid 3-tropanyl-p-hydroxyetylbromid 2-tienyl 2-thienyl 231-232 231-232 15 15 3a-(6p,7P-epoxy)tropanylmetobromid 3a- (6?, 7? Epoxy) tropanylmetobromid fenyl phenyl 217-218 217-218 16 16 3a-tropanylmetobromid 3-tropanylmetobromid fenyl phenyl 273-274 273-274 17 17 3a-(N-p-fluóretyl)nortropanylmetobromid 3a- (N-p-fluoro-ethyl) nortropanylmetobromid fenyl phenyl 215 215 18 18 3a-(6,7-dehydro)tropanyl-metobromid 3a- (6,7-dehydro) tropanyl-methobromide fenyl phenyl 170-171 170-171 19 19 3a-(N-etyl)nortropanyl-metobromid 3a- (N-ethyl) nortropanyl-methobromide fenyl phenyl 249-250 249-250 20 20 3a-(N-izopropyl)nortropanyl-metobromid 3a- (N-isopropyl) nortropanyl-methobromide fenyl phenyl 259-260 259-260 21 21 3a-tropanyletylbromid 3-tropanyletylbromid fenyl phenyl 248-249 248-249 22 22 3a-(N-etyl)nortropanyl-etylbromid 3a- (N-ethyl) nortropanyl-ethyl bromide fenyl phenyl 244-245 244-245 23 23 3a-(6p,7p-epoxy)tropanyl-etylbromid 3a- (6?, 7? Epoxy) tropanyl-ethyl bromide fenyl phenyl 226 226 24 24 3a-tropanyl-P-fluórbromid 3-tropanyl-P-fluórbromid fenyl phenyl 241 241 25 25 3a-tropanylmetobromid 3-tropanylmetobromid cyklohexyl cyclohexyl 278 278

A A R1 R1 tepl. top. temp. top. 3a-(N-p-fluóretyl)nortropanyl-metobromid 3a- (N-p-fluoro-ethyl) nortropanyl-methobromide cyklohexyl cyclohexyl 260 260 3a-tropanyl-p-fluóretylbromid 3-tropanyl-p-fluoroethyl bromide cyklohexyl cyclohexyl 233-234 233-234 3a-tropanylmetobromid 3-tropanylmetobromid cyklopentyl cyclopentyl 260 260 3a-tropanyletylbromid 3-tropanyletylbromid cyklopentyl cyclopentyl 235-236 235-236 3a-(N-etyl)nortropanyl-metobromid 3a- (N-ethyl) nortropanyl-methobromide cyklopentyl cyclopentyl 251-252 251-252 3a-(N-izopropyl)nortropanyl-metobromid 3a- (N-isopropyl) nortropanyl-methobromide cyklopentyl cyclopentyl 244-245 244-245 3a-tropanyl-p-fluóretyl-bromid 3-tropanyl-p-fluoro-ethyl-bromide cyklopentyl cyclopentyl 189-190 189-190 3a-(N-p-fluóretyl)nortropanyl-metobromid 3a- (N-p-fluoro-ethyl) nortropanyl-methobromide cyklopentyl cyclopentyl 266-267 266-267 3a-(6,7-dehydro)nortropanyl-metometáň 3a- (6,7-dehydro) nortropanyl-metometáň sulfonát sulfonate 2-tienyl 2-thienyl 225-226 225-226 3p-(6p,7p-epoxy)tropanyl-metobromid 3? (6?, 7? Epoxy) tropanyl-methobromide 2-tienyl 2-thienyl 218-220 218-220 3p-tropanylmetobromid 3p-tropanylmetobromid 2-tienyl 2-thienyl 243-244 243-244 3p-(6,7-dehydro)tropanyl-metobromid 3? (6,7-dehydro) tropanyl-methobromide 2-tienyl 2-thienyl 211-214 211-214 3a-(6,7-dehydro)tropanyl-metobromid 3a- (6,7-dehydro) tropanyl-methobromide 3-tienyl 3-thienyl 182-183* 182-183 * 3a-(6p,7p-epoxy)tropanyl-metobromÍd 3a- (6?, 7? Epoxy) tropanyl-methobromide 3-tienyl 3-thienyl 217-218 217-218 (+)-enantíomér č. 1 (+) - enantiomer no. 1 (-)-enantiomér č. 1 (-) - enantiomer no. 1 3a-(6p,7p-epoxy)tropanyl-metobromid 3a- (6?, 7? Epoxy) tropanyl-methobromide 2-furyl 2-furyl 3a-(6,7-dehydro)tropanyl-metobromid 3a- (6,7-dehydro) tropanyl-methobromide 2-furyl 2-furyl 3a-tropanylmetobromid 3-tropanylmetobromid 2-furyl 2-furyl 3a-(6p,7p-epoxy)tropanyl-metobromid 3a- (6?, 7? Epoxy) tropanyl-methobromide 2-pyridyl 2-pyridyl 3a-(6,7-dehydro)tropanyl-metobromid 3a- (6,7-dehydro) tropanyl-methobromide 2-pyridyl 2-pyridyl 3a-tropanylmetobromid 3-tropanylmetobromid 2-pyridyl 2-pyridyl 3a-tropanylmetobromid 3-tropanylmetobromid 3-tienyl 3-thienyl 3a-(6,7-dehydro)tropanyl-metobromid 3a- (6,7-dehydro) tropanyl-methobromide cyklopentyl cyclopentyl 3a-(6p,7p-epoxy)tropanyl-metobromid 3a- (6?, 7? Epoxy) tropanyl-methobromide cyklohexyl cyclohexyl 3a-(6,7-dehydro)tropanyl-metobromid 3a- (6,7-dehydro) tropanyl-methobromide cyklohexyl cyclohexyl 3a-(6p,7p-epoxy)tropanyl-metobromid 3a- (6?, 7? Epoxy) tropanyl-methobromide cyklopentyl cyclopentyl

- 19* obsahuje kryštalický metanol- 19 * contains crystalline methanol

Poznámka: všetky zlúčeniny z tejto tabuľky sa topia za rozkladu.Note: all compounds of this table melt with decomposition.

Tabuľka IIITable III

Zlúčeniny vzorca _ \Compounds of formula _ \

HO-C-CO-OA \HO-C-CO-OA

č. no. A A R1 R 1 teplota topenia hydrochlorid melting point hydrochloride 1 1 3a-(6p,7p-epoxy)tropanyl 3a- (6?, 7? Epoxy) tropanyl fenyl phenyl 246-247 246-247 2 2 3a-(6,7-dehydro)tropanyl 3a- (6,7-dehydro) tropanyl fenyl phenyl 261-262 261-262 3 3 3ct-(6p,7p-epoxy)tropanyl 3ct- (6?, 7? Epoxy) tropanyl 3-tienyl 3-thienyl 4 4 3a-(6,7-dehydro)tropanyl 3a- (6,7-dehydro) tropanyl 3-tienyl 3-thienyl 5 5 3a-tropanyl 3-tropanyl 3-tienyl 3-thienyl 6 6 3cc-(N-metyl)granatanyl 3cc- (N-methyl) granatanyl 3-tienyl 3-thienyl

Tabuľka IVTable IV

Zlúčeniny vzorcaCompounds of formula

č. no. A A R2 R 2 teplota topenia °C hydrochlorid mp ° C hydrochloride 1 1 3a-(6p,7p-epoxy)tropanyl 3a- (6?, 7? Epoxy) tropanyl H H 2 2 • 3a-(6,7-dehydro)tropanyl 3α- (6,7-dehydro) tropanyl H H 3 3 3a-(6p,7p-epoxy)tropanyl 3a- (6?, 7? Epoxy) tropanyl metyl methyl 4 4 3a-(6,7-dehydro)tropanyl 3a- (6,7-dehydro) tropanyl metyl methyl 210-212,5 210 to 212.5 5 5 3a-(6p,7p-epoxy)tropanyl 3a- (6?, 7? Epoxy) tropanyl metoxy methoxy 4 4 3a-(6,7-dehydro)tropanyl 3a- (6,7-dehydro) tropanyl metoxy methoxy

Tabuľka VTable V

Zlúčeniny vzorcaCompounds of formula

HO-C-CO-OA íHO-C-CO-OA

R1 R 1

č. no. A A R1 R 1 Ra R a 1 1 3a-(6p,7p-epoxy)tropanyl 3a- (6?, 7? Epoxy) tropanyl 2-tienyl 2-thienyl 5-metyl 5-methyl 2 2 3a-(6,7-dehydro)tropanyl 3a- (6,7-dehydro) tropanyl 2-tienyl 2-thienyl 5-metyl 5-methyl 3 3 3a-tropanyl 3-tropanyl 2-tienyl 2-thienyl 5-metyl 5-methyl 4 4 3a-(6p,7p-epoxy)tropanyl 3a- (6?, 7? Epoxy) tropanyl 2-(5-metyl)-tienyl 2- (5-methyl) thienyl 5-metyl 5-methyl 5 5 3a-(6,7-dehydro)tropanyl 3a- (6,7-dehydro) tropanyl 2-(5-metyl)-tienyl 2- (5-methyl) thienyl 5-metyl 5-methyl 6 6 3a-tropanyl 3-tropanyl 2-(5-metyl)-tienyl 2- (5-methyl) thienyl 5-metyl 5-methyl 7 7 3a-(63,73-epoxy)tropanyl 3a (63,73-epoxy) tropanyl 2-tienyl 2-thienyl 5-fluór 5-fluoro 8 8 3oc-(6,7-dehydro)tropanyl 3oc- (6,7-dehydro) tropanyl 2-tienyl 2-thienyl 5-fluór 5-fluoro 9 9 3cc-tropanyl 3CC-tropanyl 2-tienyl 2-thienyl 5-fluór 5-fluoro

č. no. A A R1 R 1 Ra R a 10 10 3a-(6p,7p-epoxy)tropanyl 3a- (6?, 7? Epoxy) tropanyl 2-(5-fIuór-tienyl) 2- (5-fluoro-thienyl) 5-fluór 5-fluoro 11 11 3a-(6,7-dehydro)tropanyl 3a- (6,7-dehydro) tropanyl 2-(5-fluór-tienyl) 2- (5-fluoro-thienyl) 5-fluór 5-fluoro 12 12 3a-tropanyl 3-tropanyl 2-(5-fluór-tienyl) 2- (5-fluoro-thienyl) 5-fluór 5-fluoro

Tabuľka VITable VI

Kvartérne zlúčeniny vzorcaQuaternary compounds of formula

R1 R 1

č. no. A A R1 R 1 Ra R a 1 1 3a-(6p,73-epoxy)tropanyl-metobromid' 3a- (6?, 73-epoxy) tropanyl-methobromide ' 2-tienyl 2-thienyl 5-metyl 5-methyl 2 2 3a-(6,7-dehydro)tropanyl-metobromid 3a- (6,7-dehydro) tropanyl-methobromide 2-tienyl 2-thienyl 5-metyl 5-methyl 3 3 3cc-tropanylmetobromid 3CC-tropanylmetobromid 2-tienyl 2-thienyl 5-metyl 5-methyl 4 4 3a-(6p,7p-epoxy)tropanyl-metobromid 3a- (6?, 7? Epoxy) tropanyl-methobromide 2-(5-metyl)-tienyl 2- (5-methyl) thienyl 5-metyl 5-methyl 5 5 3a-(6,7-dehydro)tropanyl-metobromid 3a- (6,7-dehydro) tropanyl-methobromide 2-(5-metyl)-tienyl 2- (5-methyl) thienyl 5-metyl 5-methyl 6 6 3a-tropanylmetobromid 3-tropanylmetobromid 2-(5-metyl)-tienyl 2- (5-methyl) thienyl 5-metyl 5-methyl 7 7 3a-(6p,7p-epoxy)tropanyl-metobromid 3a- (6?, 7? Epoxy) tropanyl-methobromide 2-tienyl 2-thienyl 5-fluór 5-fluoro 8 8 3a-(6,7-dehydro)tropanyl-metobromid 3a- (6,7-dehydro) tropanyl-methobromide 2-tienyl 2-thienyl 5-fluór 5-fluoro 9 9 3a-tropanylmetobromid 3-tropanylmetobromid 2-tienyl 2-thienyl 5-fluór 5-fluoro 10 10 3a-(6p,7p-epoxy)tropanyl-metobromid 3a- (6?, 7? Epoxy) tropanyl-methobromide 2-(5-fluór) tienyl 2- (5-fluoro) thienyl 5-fluór 5-fluoro 11 11 3a-(6,7-dehydro)tropanyl-metobromid 3a- (6,7-dehydro) tropanyl-methobromide 2-(5-fluór)tienyl 2- (5-fluoro) thienyl 5-fluór 5-fluoro 12 12 3a-tropanylmetobromid 3-tropanylmetobromid 2-(5-fluór)tienyl 2- (5-fluoro) thienyl 5-fluór 5-fluoro

-22Tabuľka VII-22Table VII

Zlúčeniny vzorcaCompounds of formula

HO-C-CO-OAHO-C-CO-OA

R1 R 1

č. no. A A R1 R 1 tepl.top. °C tepl.top. ° C 1 1 3a-(6p,7p-epoxy)tropanyl-metobromid 3a- (6?, 7? Epoxy) tropanyl-methobromide fenyl phenyl 211-212 211-212 2 2 3a-(6,7-dehydro)tropanyl-metobromid 3a- (6,7-dehydro) tropanyl-methobromide fenyl phenyl 158-160* 158-160 * 3 3 3a-(6p,7p-epoxy)tropanyl-metobromid 3a- (6?, 7? Epoxy) tropanyl-methobromide 3-tienyl 3-thienyl 4 4 3a-(6,7-dehydro)tropanyl-metobromid 3a- (6,7-dehydro) tropanyl-methobromide 3-tienyl 3-thienyl 5 5 3cc-tropanylmetobromid 3CC-tropanylmetobromid 3-tienyl 3-thienyl 6 6 3a-(N-metyl)granatanyl-metobromid 3a- (N-methyl) granatanyl-methobromide 3-tienyl 3-thienyl

* s kryštalickým metanolom* with crystalline methanol

Tabuľka VIIITable VIII

Zlúčeniny vzorcaCompounds of formula

r2-C-co-oa \r 2 -C-co-oa \

č. no. A A R2 R 2 tepl. top. °C temp. top. ° C 1 1 3a-(6p,7p-epoxy)tŕopanyl-metobromid 3a- (6?, 7? Epoxy) tropanyl-methobromide H H 2 2 3a-(6,7-dehydro)tropanyl- metobromid 3α- (6,7-dehydro) tropanyl-metobromide H H 3 3 3a-(6p,7p-epoxy)tropanyl-metobromid 3a- (6?, 7? Epoxy) tropanyl-methobromide metyl methyl 4 4 3a-(6,7-dehydro)tropanyl-metobromid 3a- (6,7-dehydro) tropanyl-methobromide metyl methyl 206-208 206-208 5 5 3a-tropanylmetobromid metoxy 3α-tropanylmetobromide methoxy 6 6 3a-(N-metyl)tropanyl-metobromid 3a- (N-methyl) tropanyl-methobromide metoxy methoxy

Claims (12)

PATENTOVÉ NÁROKYPATENT CLAIMS 1. Zlúčeniny všeobecného vzorca ICompounds of formula I Ra r1-Č-CO-OA iR a r 1 -C-CO-OA i R2 R 2 d) kde(d) where A znamená skupinu všeobecného vzorca II kdeA represents a group of formula II wherein Q znamená jednu z dvojväzbových skupín -CH2-CH2, -CH2-CH2-CH2-, -CH=CH-,Q represents one of the divalent groups -CH 2 -CH 2 , -CH 2 -CH 2 -CH 2 -, -CH = CH-, -CH - CHa-CH-CHa R znamená alkyl s 1 až 4 atómami uhlíka, prípadne substituovaný atómom halogénu alebo hydroxyskupinou,R is C 1 -C 4 alkyl optionally substituted by halogen or hydroxy, R' znamená alkyl s 1 až 4 atómami uhlíka a R a R' môžu spolu tvoriť alkylénový zvyšok s 4 až 6 atómami uhlíka, pričom sa pozitívny náboj dusíkového atómu vyrovnaná ekvivalentom aniónu X(_) R 'is C 1 -C 4 alkyl and R and R' can be taken together to form a C 4 -C 6 alkylene moiety, whereby the positive charge of the nitrogen atom is offset by the anion X equivalent (_) R1 znamená tienyl, fenyl, furyl, cyklopentyl alebo cyklohexyl, pričom všetky zvyšky môžu byť substituované metylovými zvyškami, tienyl a fenyl tiež atómami chlóru alebo flóruR 1 is thienyl, phenyl, furyl, cyclopentyl or cyclohexyl, each of these radicals to be substituted by methyl radicals, phenyl and thienyl also chlorine or fluorine -25R2 znamená atóm vodíka, hydroxyskupinu, alkoxyskupinu alebo alkylovú skupinu, obidve s 1 až 4 atómami uhlíka-25R 2 represents a hydrogen atom, a hydroxy group, an alkoxy group or an alkyl group, both having 1 to 4 carbon atoms Ŕa znamená atóm vodíka, atóm flóru, chlóru alebo metylovú skupinu.Ŕ a represents a hydrogen atom, a fluorine atom, a chlorine atom or a methyl group. 2. Zlúčeniny podľa nároku 1, kde R1 znamená 2-tienyl.Compounds according to claim 1, wherein R 1 is 2-thienyl. 3. Zlúčeniny podľa nároku 1 alebo 2, kde R2 znamená hydroxyskupinu.Compounds according to claim 1 or 2, wherein R 2 is hydroxy. 4. Zlúčeniny podľa nároku 1, 2 alebo 3, kde A znamenáCompounds according to claim 1, 2 or 3, wherein A represents R a Xw má význam, uvedený v nároku 1 a R' má význam uvedený v nároku 1, s výnimkou atómu vodíka.X and R w is as defined in claim 1 and R is as defined in claim 1, except hydrogen. 5. Zlúčeniny podľa nároku 1 až 4, kde R* znamená 2-tienyl a A znamená skupinuCompounds according to claims 1 to 4, wherein R * represents 2-thienyl and A represents a group - 26alebo vo forme 3α-, kde Xí_) znamená ekvivalent aniónu, s výhodou Bi0 alebo CH3Sof26 or in the form of 3α-, wherein X 1) is an anion equivalent, preferably Bi 0 or CH 3 Sof 6. Zlúčeniny všeobecného vzorca podľa nároku 1, vo forme 3α-, ako metobromidy alebo metometánsulfonáty.Compounds of formula I according to claim 1, in the form of 3α-, such as metobromides or methanesulfonates. 7. Spôsob výroby zlúčenín podľa nárokov 1 až 6, vyznačujúci sa t ý m, že sa ester všeobecného vzorca IV r1-C-C0-0R iA process for the preparation of the compounds according to claims 1 to 6, characterized in that the ester of the general formula (IV): (IV)(IV) -27kde R znamená alkyl s 1 až 4 atómami uhlíka a R1, R2 a R3 majú význam, uvedený v nároku 1, podrobí výmene esterových skupín s aminoalkoholom všeobecného vzorca V kde-27 where R is C 1 -C 4 alkyl and R 1 , R 2 and R 3 are as defined in claim 1, undergoes ester exchange with an amino alcohol of formula V wherein: Q má význam, uvedený v nároku 1 a Q znamená =NR alebo =NH, v inertnom organickom rozpúšťadle alebo v tavenine, za prítomnosti katalyzátoru výmeny esterových skupín a získané zlúčeniny všeobecného vzorca VI sa (VI)Q is as defined in claim 1 and Q is = NR or = NH, in an inert organic solvent or in the melt, in the presence of an ester exchange catalyst and the compound of formula (VI) obtained (VI) a) v prípade, že Q znamená =NR, kvarternizujú pôsobením reaktívneho monoderivátu alkánu vzorca Z-(alkyl s 1 až 4 atómami uhlíka), kde Z je ľahko odštiepiteľná skupina, alebo sa(a) when Q is = NR, quaternize by treatment with a reactive mono-derivative of an alkane of the formula Z- (alkyl of 1 to 4 carbon atoms), where Z is a readily cleavable group, or b) v prípade, že Q znamená =NH, kvarternizujú disubstituovaným alkánom vzorca Z-(alkylén s 4 až 6 atómami uhlíka)-Z bez izolácie medziproduktov.b) when Q is = NH, quaternize with a disubstituted alkane of formula Z- (C 4 -C 6 alkylene) -Z without isolation of the intermediates. 8. Medziprodukt všeobecného vzorca VI, kde Q, Q, Ra, R1 a R2 majú význam uvedený v nároku 1, ako aj adičné soli týchto látok s kyselinami s výnimkou tropínesterov fenyl-2-tienylgiykolovej, 2,2'-dithienylglykolovej a 3,3'-28ditienylglykolovej kyseliny na prípravu zlúčeniny vzorca I podľa nároku 1.Intermediate of formula VI, wherein Q, Q, R a , R 1 and R 2 are as defined in claim 1, as well as acid addition salts thereof with the exception of phenyl-2-thienylgiylcolic, 2,2'-dithienylglycolic tropinesters and 3,3'-28-dithienylglycolic acid for the preparation of a compound of formula I according to claim 1. 9. Medziprodukt podľa nároku 8, všeobecného vzorca VI, ktorým je9. An intermediate according to claim 8, which is S \WITH \ 10. Farmaceutický prostriedok s anticholinergickými účinkami, na liečbu ochorení dýchacích ciest a sínusovej bradykardie, vyznačujúci sa tým, žé obsahuje zlúčeniny podľa nárokov 1 až 6 spolu s pomocnými látkami a/alebo nosičmi.Pharmaceutical composition with anticholinergic effects, for the treatment of respiratory diseases and sinus bradycardia, characterized in that it contains the compounds according to claims 1 to 6 together with adjuvants and / or carriers. 11. Použitie zlúčenín podľa nárokov 1 až 6 na prípravu farmaceutických prostriedkov s anticholinergickým účinkom.Use of the compounds according to claims 1 to 6 for the preparation of pharmaceutical compositions having anticholinergic activity. 12. Použitie zlúčenín podľa 1 až 6 na prípravu farmaceutických prostriedkov na liečbu ochorení dýchacích ciest a sínusovej bradykardie.Use of the compounds according to 1 to 6 for the preparation of pharmaceutical compositions for the treatment of respiratory diseases and sinus bradycardia.
SK4523-90A 1989-09-16 1990-09-17 Esters of thienyl carboxylic acids and amino alcohols, method for producing thereof, intermediates, pharmaceutical compositions containing same and their use SK279453B6 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3931041A DE3931041C2 (en) 1989-09-16 1989-09-16 Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them

Publications (2)

Publication Number Publication Date
SK452390A3 true SK452390A3 (en) 1998-11-04
SK279453B6 SK279453B6 (en) 1998-11-04

Family

ID=6389619

Family Applications (1)

Application Number Title Priority Date Filing Date
SK4523-90A SK279453B6 (en) 1989-09-16 1990-09-17 Esters of thienyl carboxylic acids and amino alcohols, method for producing thereof, intermediates, pharmaceutical compositions containing same and their use

Country Status (33)

Country Link
US (1) USRE39820E1 (en)
EP (1) EP0418716B1 (en)
JP (1) JPH0730074B2 (en)
KR (1) KR0168432B1 (en)
AT (1) ATE103914T1 (en)
AU (1) AU642913B2 (en)
BG (1) BG61295B2 (en)
CA (1) CA2066248C (en)
CZ (1) CZ284589B6 (en)
DD (1) DD297647A5 (en)
DE (3) DE3931041C2 (en)
DK (1) DK0418716T3 (en)
ES (1) ES2052125T3 (en)
FI (1) FI114395B (en)
HR (1) HRP940723B1 (en)
HU (2) HU208823B (en)
IE (1) IE65528B1 (en)
IL (1) IL95691A (en)
LU (1) LU90949I2 (en)
MX (1) MX9203150A (en)
NL (1) NL300084I2 (en)
NO (2) NO301478B1 (en)
NZ (1) NZ235306A (en)
PH (1) PH31617A (en)
PL (1) PL168468B1 (en)
PT (1) PT95312B (en)
RU (1) RU2073677C1 (en)
SI (1) SI9011744B (en)
SK (1) SK279453B6 (en)
UA (1) UA41272C2 (en)
WO (1) WO1991004252A1 (en)
YU (1) YU47800B (en)
ZA (1) ZA907338B (en)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (en) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them
DE4108393A1 (en) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg NEW ESTERS BI-AND TRICYCLIC AMINO ALCOHOLS, THEIR PREPARATION AND THEIR USE IN MEDICINAL PRODUCTS
US5770738A (en) * 1992-03-05 1998-06-23 Boehringer Ingelheim Kg Esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions
DE19921693A1 (en) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
GB0009592D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
IL154175A0 (en) 2000-08-05 2003-07-31 Glaxo Group Ltd 17. beta.-carbothioate 17. alpha-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
WO2002030389A1 (en) 2000-10-12 2002-04-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel tiotropium-containing inhalation powder
MEP40008A (en) * 2000-10-12 2011-02-10 Boehringer Ingelheim Pharma Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
EP1837021A3 (en) * 2000-10-31 2008-03-19 Boehringer Ingelheim Pharma GmbH & Co. KG Inhalative solution formulation containing a tiotropium salt
DE10064816A1 (en) * 2000-12-22 2002-06-27 Boehringer Ingelheim Pharma Production of tiotropium bromide useful as an anticholinergic comprises oxidation of di-(2-thienyl)-glycolic acid tropenol ester and subsequent quaternisation
SK287414B6 (en) 2000-12-28 2010-09-07 Laboratorios Almirall, S.A. Quinuclidine derivatives and compositions contain thereof
US6506900B1 (en) 2001-01-31 2003-01-14 Boehringer Ingelheim Pharma Ag Process for preparing a scopine ester intermediate
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
AU2002253342B2 (en) 2001-04-30 2007-01-04 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
DE10126924A1 (en) * 2001-06-01 2002-12-05 Boehringer Ingelheim Pharma Inhalation capsule contains powdered mixture of tiotropium and auxiliary, for treating asthma or chronic obstructive pulmonary disease, having capsule material of low moisture content to improve stability
KR101011353B1 (en) * 2001-06-22 2011-01-28 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 Crystalline anticholinergic, method for its production and pharmaceutical composition comprising the same
US6608055B2 (en) 2001-06-22 2003-08-19 Boehringer Ingelheim Pharma Kg Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition
US6610849B2 (en) * 2001-06-28 2003-08-26 Boehringer Ingelheim Pharma Kg Process for the manufacture of tropenol
DE10141377A1 (en) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Scattering process for the production of powder formulations
US6890920B2 (en) 2001-10-26 2005-05-10 Pharmacia & Upjohn Company Quaternary ammonium compounds
DE10200943A1 (en) * 2002-01-12 2003-07-24 Boehringer Ingelheim Pharma Process for the preparation of scopine esters
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
DE10203749A1 (en) * 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma New anticholinergics, process for their preparation and their use as medicines
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
GB0203193D0 (en) * 2002-02-11 2002-03-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
WO2003068233A1 (en) * 2002-02-11 2003-08-21 Pfizer Limited Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases
DE10212264A1 (en) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Crystalline micronisate, process for its preparation and its use for the manufacture of a medicament
US7309707B2 (en) * 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
DE10214264A1 (en) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA suspension formulations of an anhydrate
UA80123C2 (en) 2002-04-09 2007-08-27 Boehringer Ingelheim Pharma Inhalation kit comprising inhalable powder of tiotropium
DE10216036A1 (en) 2002-04-11 2003-10-23 Boehringer Ingelheim Pharma Aerosol formulation for inhalation containing a tiotropium salt
DE10224091A1 (en) * 2002-05-31 2003-12-11 Boehringer Ingelheim Pharma Technical process for the production of tropenol
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
US8481518B2 (en) * 2003-01-16 2013-07-09 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
WO2004106333A1 (en) 2003-05-28 2004-12-09 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
US7968717B2 (en) 2003-11-03 2011-06-28 Boehringer Ingelhein International Gmbh Crystalline anhydrate with anticholinergic efficacy
SG137859A1 (en) * 2003-11-03 2007-12-28 Boehringer Ingelheim Int Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
CN1875020B (en) 2003-11-03 2010-04-28 贝林格尔.英格海姆国际有限公司 Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
SI1682542T1 (en) * 2003-11-03 2010-04-30 Boehringer Ingelheim Int Novel crystalline anhydride with anticholinergic effect
SE0303570L (en) 2003-12-03 2005-06-04 Microdrug Ag Moisture-sensitive medical product
EP1785421A1 (en) * 2004-08-30 2007-05-16 Ono Pharmaceutical Co., Ltd. Tropan compound
AU2006243238B2 (en) 2005-05-02 2012-05-24 Boehringer Ingelheim International Gmbh Novel crystalline forms of tiotropium bromide
RU2007144531A (en) * 2005-05-02 2009-06-10 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) NEW CRYSTAL FORMS OF THIOTROPYBROMIDE
DE102005035112A1 (en) 2005-07-27 2007-02-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg A new process for the preparation of tiotropium salts using N-methylscopinium salts soluble in organic solvents
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
US20070088030A1 (en) 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
DE102005059602A1 (en) * 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Micronization process
US20070167480A1 (en) * 2005-12-19 2007-07-19 Sicor Inc. Pure and stable tiotropium bromide
US9108962B2 (en) 2005-12-19 2015-08-18 Sicor, Inc. Forms of tiotropium bromide and processes for preparation thereof
PL2123650T3 (en) * 2005-12-19 2012-09-28 Sicor Inc Novel form of tiotropium bromide and process for preparation thereof
DE602006020620D1 (en) * 2006-01-04 2011-04-21 Boehringer Ingelheim Pharma USE OF TIOTROPIUM SALTS IN THE TREATMENT OF MODERN PERSISTENT ASTHMA
ES2298049B1 (en) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. PROCEDURE FOR MANUFACTURING BROMIDE OF 3 (R) - (2-HIDROXI-2,2-DITIEN-2-ILACETOXI) -1- (3-PHENOXIPROPIL) -1-AZONIABICICLO (2.2.2) OCTANO.
PT2046787E (en) 2006-08-01 2011-06-15 Glaxo Group Ltd Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
EP1923393A1 (en) * 2006-11-17 2008-05-21 Boehringer Ingelheim Pharma GmbH & Co. KG Crystalline form of tiotropium bromide and urea
EP1925295A1 (en) * 2006-11-22 2008-05-28 Boehringer Ingelheim Pharma GmbH & Co. KG Stable powder formulation containing a new antichinolinergic agent
GB0716026D0 (en) 2007-08-16 2007-09-26 Norton Healthcare Ltd An inhalable medicament
CA2608561A1 (en) * 2007-10-29 2009-04-29 Carl Paluszkiewicz Motorcycle wind deflector accessory support
CN101918401A (en) * 2008-01-10 2010-12-15 基因里克斯(英国)有限公司 Novel process for the preparation of scopine esters
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CN102014779B (en) 2008-05-09 2014-10-22 赫莱拉公司 Systems, assemblies, and methods for treating a bronchial tree
EP2172190A1 (en) 2008-10-02 2010-04-07 Laboratorios Liconsa, S.A. Inhalable particles comprising tiotropium
EP2403851B1 (en) 2009-03-06 2015-06-17 Mahmut Bilgic New crystalline forms of tiotropium bromide
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL3111926T3 (en) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
CA2931876A1 (en) * 2009-08-07 2011-02-10 Generics [Uk] Limited Anhydrate of tiotropium bromide
WO2011015883A1 (en) 2009-08-07 2011-02-10 Generics [Uk] Limited Dichloromethane solvate of tiotropium bromide and its use
WO2011015884A1 (en) 2009-08-07 2011-02-10 Generics [Uk] Limited Process to prepare scopine esters
TR200907236A2 (en) 2009-09-23 2011-04-21 Bi̇lgi̇ç Mahmut Transport of Tiotropium dry powder formulation in blister pack.
TR200907237A2 (en) 2009-09-23 2011-04-21 Bi̇lgi̇ç Mahmut Tiotropium dry powder combination
CN107049479B (en) 2009-10-27 2020-10-16 努瓦拉公司 Delivery device with coolable energy emitting assembly
EP4111995A1 (en) 2009-11-11 2023-01-04 Nuvaira, Inc. Device for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
TR200909790A2 (en) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Combination of dry powder containing a combination of tiotropium, formoterol and a chromoglycic acid derivative.
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR200909788A2 (en) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Dry powder formulation suitable for inhalation with tiotropium
WO2011093809A2 (en) 2010-01-28 2011-08-04 Mahmut Bilgic Dry powder pharmaceutical composition comprising tiotropium and ciclesonide
TR201000679A2 (en) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Dry powder formulations containing a pharmaceutical combination.
TR200909793A2 (en) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Combination of dry powder containing a combination of tiotropium, mometasone and a chromoglycic acid derivative.
WO2011093812A2 (en) 2010-01-28 2011-08-04 Mahmut Bilgic Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
TR200909789A2 (en) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Dry powder combination containing tiotropium, budesonide and a chromoglycic acid derivative combination
TR201000681A2 (en) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Dry powder formulations inhaled.
TR200909792A2 (en) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Dry powder combination containing tiotropium, corticosteroid and a combination of chromoglycic acid derivative
WO2011093810A2 (en) 2010-01-28 2011-08-04 Bilgic Mahmut Dry powder pharmaceutical composition comprising tiotropium and mometasone
EP2528600B1 (en) 2010-01-28 2016-06-29 Mahmut Bilgic Dry powder pharmaceutical composition comprising tiotropium and fluticasone
TR201000733A2 (en) 2010-02-02 2011-08-22 Bi̇lgi̇ç Mahmut Pharmaceutical compositions comprising fluticasone, tiotropium and sodium chromoglycate.
TR201005221A2 (en) 2010-04-01 2012-01-23 Bi̇lgi̇ç Mahmut Improved synthesis method.
TR201002520A2 (en) 2010-04-01 2010-05-21 Bi̇lgi̇ç Mahmut Tiotropium bromide manufacturing method.
TR201005222A2 (en) 2010-04-01 2011-10-21 Bi̇lgi̇ç Mahmut Tiotropium bromide synthesis method
US8957209B2 (en) 2010-04-01 2015-02-17 Mahmut Bilgic Methods for the synthesis of tiotropium bromide
TR201007108A2 (en) 2010-08-25 2012-03-21 B�Lg�� Mahmut New tiotropium bromide crystal and production method.
TR201101897A2 (en) 2011-02-28 2012-09-21 Bi̇lgi̇ç Mahmut Crystal material containing tiotropium bromide
TR201111589A2 (en) 2011-03-03 2012-09-21 Bi̇lgi̇ç Mahmut Tiotropium bromide anhydrous crystal form.
TR201102068A2 (en) 2011-03-03 2012-09-21 Bi̇lgi̇ç Mahmut Crystalline substances containing tiotropium bromide
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
ITRM20110508A1 (en) 2011-09-27 2013-03-28 Lusochimica Spa PROCESS FOR THE PREPARATION OF SCOPINA'S ESTERS.
US8680297B2 (en) 2011-10-06 2014-03-25 Drug Process Licensing Assoc., LLC Manufacturing process for tiotropium bromide
CZ304368B6 (en) 2011-11-28 2014-04-02 Zentiva, K.S. Tiotropium bromide mixed solvate and process for preparing thereof
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
PL2607351T3 (en) * 2011-12-22 2017-08-31 Cerbios-Pharma S.A. Continuous process for the alkylation of cyclic tertiary amines
WO2013109213A2 (en) 2012-01-16 2013-07-25 Mahmut Bilgic Pharmaceutical formulations comprising tiotropium
CZ201241A3 (en) 2012-01-20 2013-07-31 Zentiva, K.S. Novel polymorphous forms of thiotropium iodide and process for preparing thereof
PT106142B (en) 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A PROCESS FOR THE PREPARATION OF TIOTROPE BROMIDE
WO2014007773A1 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions comprising muscarinic receptor antagonist and sorbitol
WO2013127738A1 (en) 2012-02-28 2013-09-06 Boehringer Ingelheim International Gmbh Novel propellant-gas-containing tiotropium formulation
CZ304808B6 (en) * 2012-03-16 2014-11-05 Zentiva, K.S. Process for preparing scopine ester of di-(2- thienyl)glycolic acid, an intermediate in the synthesis of tiotropium bromide and a new form thereof
CZ305012B6 (en) 2012-03-30 2015-03-25 Zentiva, K.S. Process for preparing scopine ester of di-(2-thienyl)glycolic acid, an intermediate in the synthesis of tiotropium bromide
US20150174064A1 (en) 2012-07-05 2015-06-25 Arven IIac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and glucose anhydrous
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
EP2705838A1 (en) 2012-09-06 2014-03-12 Xspray Microparticles Ab Tiotropium preparations
CN104797579A (en) 2012-11-05 2015-07-22 赞蒂瓦有限合伙公司 Stabilization of tiotropium solvates
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
CN105324106A (en) 2013-04-01 2016-02-10 普马特里克斯营业公司 Tiotropium dry powders
EP2913332A1 (en) * 2014-02-27 2015-09-02 Euticals S.P.A. Crystalline form of tiotropium bromide with lactose
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
US10653683B2 (en) 2015-05-18 2020-05-19 Glenmark Specialty S.A. Tiotropium inhalation solution for nebulization
JP6782706B2 (en) 2015-05-18 2020-11-11 グレンマーク・スペシャルティー・エスエー Tiotropium inhalation solution for spraying
US9987260B2 (en) 2015-05-18 2018-06-05 Glenmark Specialty S.A. Tiotropium inhalation solution for nebulization
KR101748796B1 (en) 2015-09-30 2017-06-19 한미약품 주식회사 Inhalation capsule with enhanced delivery rate of active ingredients
EP3159278A1 (en) 2015-10-23 2017-04-26 Arven Ilac Sanayi Ve Ticaret A.S. Blister for tiotropium bromide inhalable formulation
JP2019500916A (en) 2015-10-23 2019-01-17 アーヴェン イラチュ サナイ ヴェ ティヂャレット エー． エス．Ａｒｖｅｎ Ｉｌａｃ Ｓａｎａｙｉ Ｖｅ Ｔｉｃａｒｅｔ Ａ．Ｓ． Blister for inhalation formulation of tiotropium bromide
WO2017138896A1 (en) 2016-02-11 2017-08-17 Sima Patent Ve Lisanslama Hizmetleri Ltd. Şti Crystalline form of tiotropium bromide anhydrate
CN106467535A (en) * 2016-08-28 2017-03-01 杭州百诚医药科技股份有限公司 One kind prepares the purifying process of 2,2 pairs of (2 thienyl) glycolic Rhizoma Scopoliae Japonicae esters
WO2018055642A1 (en) * 2016-09-23 2018-03-29 Gbr Laboratories Pvt. Ltd. A process for preparing tiotropium bromide and intermediates thereof
EA201990605A1 (en) 2016-10-14 2019-10-31 SPRAYED THIOTROPY AND FORMOTEROL COMPOSITIONS
AU2017363041A1 (en) 2016-11-16 2019-04-11 Glenmark Specialty S.A. Nebulized tiotropium
US20200215051A1 (en) 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol
WO2023283441A1 (en) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, methods and systems for aerosol drug delivery
CN114213408B (en) * 2021-12-15 2023-03-31 台州仙琚药业有限公司 Preparation method of tiotropium bromide
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB845056A (en) 1957-07-05 1960-08-17 Egyt Gyogyszervegyeszeti Gyar Improvements in or relating to tropane derivatives
DE1166787B (en) * 1960-07-09 1964-04-02 Boehringer & Soehne Gmbh Process for the production of new garnetanol (3ª ‰) esters and their hydrohalides
GB955535A (en) * 1962-10-22 1964-04-15 Boehringer & Soehne Gmbh New n-substituted norgranatanol-(3ª‰)-esters
DE2046659A1 (en) 1970-01-28 1972-03-23
US3808263A (en) * 1970-05-12 1974-04-30 Tanabe Seiyaku Co 6,6-dimethyl-9-alkyl-9-azabicyclo(3.3.1)nonan-3-ols
US3673195A (en) * 1970-05-25 1972-06-27 Tanabe Seiyaku Co Derivatives of 6,6,9-tri-lower alkyl-9-azabicyclo(3.3.1) nonan-3{60 -or 3{62 -ol
US4353922A (en) * 1981-03-13 1982-10-12 Syntex (U.S.A.) Inc. Anticholinergic bronchodilators
DE3546218A1 (en) 1985-12-27 1987-07-02 Madaus & Co Dr AZONIA SPIRONORTROPANOLESTER, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENT
DE3931041C2 (en) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them

Also Published As

Publication number Publication date
SI9011744B (en) 1999-12-31
HRP940723A2 (en) 1997-06-30
NL300084I1 (en) 2002-05-01
KR0168432B1 (en) 1999-01-15
FI921087A0 (en) 1992-03-13
IL95691A (en) 1996-07-23
PH31617A (en) 1999-01-12
DE59005250D1 (en) 1994-05-11
UA41272C2 (en) 2001-09-17
DE3931041A1 (en) 1991-03-28
IE903342A1 (en) 1991-04-10
BG61295B2 (en) 1997-04-30
USRE39820E1 (en) 2007-09-04
ATE103914T1 (en) 1994-04-15
IE65528B1 (en) 1995-11-01
AU6431890A (en) 1991-04-18
AU642913B2 (en) 1993-11-04
CA2066248C (en) 1998-08-04
EP0418716A1 (en) 1991-03-27
JPH05502438A (en) 1993-04-28
CA2066248A1 (en) 1991-03-17
SI9011744A (en) 1997-10-31
PL286900A1 (en) 1991-12-02
HU9200857D0 (en) 1992-05-28
PT95312A (en) 1991-05-22
DK0418716T3 (en) 1994-05-02
HU210612A9 (en) 1995-05-29
RU2073677C1 (en) 1997-02-20
NL300084I2 (en) 2002-08-01
DE10299026I1 (en) 2002-11-07
FI114395B (en) 2004-10-15
HRP940723B1 (en) 1999-10-31
DD297647A5 (en) 1992-01-16
HU208823B (en) 1994-01-28
ZA907338B (en) 1992-08-26
LU90949I2 (en) 2002-10-30
MX9203150A (en) 1992-07-01
JPH0730074B2 (en) 1995-04-05
NZ235306A (en) 1997-06-24
NO921002L (en) 1992-03-13
WO1991004252A1 (en) 1991-04-04
DE3931041C2 (en) 2000-04-06
EP0418716B1 (en) 1994-04-06
DE10299026I2 (en) 2004-07-01
CZ284589B6 (en) 1999-01-13
YU47800B (en) 1996-01-09
PT95312B (en) 1997-06-30
YU174490A (en) 1993-10-20
ES2052125T3 (en) 1994-07-01
KR910006272A (en) 1991-04-29
IL95691A0 (en) 1991-06-30
NO301478B1 (en) 1997-11-03
CZ452390A3 (en) 1998-11-11
SK279453B6 (en) 1998-11-04
NO921002D0 (en) 1992-03-13
NO2002009I2 (en) 2004-10-11
PL168468B1 (en) 1996-02-29
HUT60740A (en) 1992-10-28

Similar Documents

Publication Publication Date Title
SK452390A3 (en) Esters of thienyl carboxylic acids and amino alcohols, process for their preparation, intermediate products, pharmaceutical compositions containing same and their use
US5610163A (en) Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
KR100307274B1 (en) Esters of bicyclic and tricyclic amino alcohols, methods for their preparation and pharmaceutical compositions comprising the same
US5770738A (en) Esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions
US7576105B2 (en) Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives
JPH02202890A (en) New compound, its manufacture, and drug composition containing it
JP2643274B2 (en) Imidazo [1,2-a] pyridine derivative
IE63670B1 (en) Esters of hexahydro-8-hydroxy-2,6-methano-2h-quinolizin-3(4h)-one and related compounds
JP2531304B2 (en) Novel aminopiperazine derivative
CZ424289A3 (en) Amidine and guanidine derivatives, processes of their preparation and pharmaceutical preparations in which they are comprised
EP0414422B1 (en) 2-Oxo-1-oxa-8-azaspiro [4,5] decane derivatives, processes for their preparation and pharmaceutical compositions thereof
IE42618B1 (en) New pharmaceutical compositions containing piperidyl-indole derivatives
EP1558610B1 (en) Substituted aminoquinuclidine compounds and their use as delta-opioid receptor ligands
MX2011005109A (en) 8-azabicyclo [3.2.1]oct-2-ene derivatives and their use as mono-amine neurotransmitter re-uptake inhibitors.
CZ97191A3 (en) heterocyclic compounds

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20100917

SPCY Application to extend an spc

Free format text: PRODUCT NAME: TIOTROPIUM BROMID; NAT. REGISTRATION NO/DATE: 14/0032/02-S 20020308; FIRST REGISTRATION: NL RVG 26191 20011009

Spc suppl protection certif: DO 3; 2-2002

Filing date: 20020730

SPCE Expiry of an spc

Free format text: PRODUCT NAME: TIOTROPIUM BROMID; NAT. REGISTRATION NO/DATE: 14/0032/02-S 20020308; FIRST REGISTRATION: NL RVG 26191 20011009

Spc suppl protection certif: DO 3;2-2002

Expiry date: 20160318